US equities |
MU $989.04 ▲+0.00% SNDK $1,487.33 ▲+0.00% NVDA $226.32 ▲+0.00% SKHY $162.23 ▲+0.00% GS $893.95 ▲+0.00% UNH $378.52 ▲+0.00% JPM $334.30 ▲+0.00% INTC $101.35 ▲+0.00%
FinancialContent

Eliem Therapeutics, Inc - Common Stock (NQ:ELYM)

5.110 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eliem Therapeutics, Inc - Common Stock

News headline image
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Announces Additions to its Leadership Team
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Reports Second Quarter Financial Results
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
From Eliem Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eliem Therapeutics Provides Update on Pipeline Progress
From Eliem Therapeutics, Inc.
Via GlobeNewswire